WO2018171698A1 - Dérivés d'un hétéroaryle et d'une pyrimidinone, leur procédé de préparation et leur application - Google Patents
Dérivés d'un hétéroaryle et d'une pyrimidinone, leur procédé de préparation et leur application Download PDFInfo
- Publication number
- WO2018171698A1 WO2018171698A1 PCT/CN2018/080117 CN2018080117W WO2018171698A1 WO 2018171698 A1 WO2018171698 A1 WO 2018171698A1 CN 2018080117 W CN2018080117 W CN 2018080117W WO 2018171698 A1 WO2018171698 A1 WO 2018171698A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- heteroaryl
- cycloalkyl
- aryl
- alkyl
- Prior art date
Links
- 0 *c1c(*)[s]c(N(C[C@](C2=CC=CC=C(*)C2)O*)C(N2*)=O)c1C2=O Chemical compound *c1c(*)[s]c(N(C[C@](C2=CC=CC=C(*)C2)O*)C(N2*)=O)c1C2=O 0.000 description 4
- ZZWWXIBKLBMSCS-FQEVSTJZSA-N CC(C)(C(O)=O)N(C(c1c(N2C[C@@H](c3ccccc3OC)OC3CCOCC3)[s]c(-c3ncc[o]3)c1C)=O)C2=O Chemical compound CC(C)(C(O)=O)N(C(c1c(N2C[C@@H](c3ccccc3OC)OC3CCOCC3)[s]c(-c3ncc[o]3)c1C)=O)C2=O ZZWWXIBKLBMSCS-FQEVSTJZSA-N 0.000 description 2
- QHAATLPCOPACFW-NRFANRHFSA-N CC(C)(C(NOC)=O)N(C(c1c(N2C[C@@H](c3ccccc3OC)OC3CCOCC3)[s]c(-c3ncc[o]3)c1C)=O)C2=O Chemical compound CC(C)(C(NOC)=O)N(C(c1c(N2C[C@@H](c3ccccc3OC)OC3CCOCC3)[s]c(-c3ncc[o]3)c1C)=O)C2=O QHAATLPCOPACFW-NRFANRHFSA-N 0.000 description 1
- APGNVOSIXZYEPK-UHFFFAOYSA-N CC(C)(C)OC(C(C)(C)N(C(c1c(N2)[s]c(Br)c1C)=O)C2=O)=O Chemical compound CC(C)(C)OC(C(C)(C)N(C(c1c(N2)[s]c(Br)c1C)=O)C2=O)=O APGNVOSIXZYEPK-UHFFFAOYSA-N 0.000 description 1
- WAMWUBSWBISHFO-ZPHPHTNESA-N CC(C)(C)OC(C(C)(C)N(C(c1c(N2C/C(/c3ccccc3OC)=C/OC3CCOCC3)[s]c(Br)c1C)=O)C2=O)=O Chemical compound CC(C)(C)OC(C(C)(C)N(C(c1c(N2C/C(/c3ccccc3OC)=C/OC3CCOCC3)[s]c(Br)c1C)=O)C2=O)=O WAMWUBSWBISHFO-ZPHPHTNESA-N 0.000 description 1
- NFBQJHOKTSYEDJ-UHFFFAOYSA-N CC(C)(C)OC(C(C)(C)N(C(c1c(N2CC(c3ccccc3OC)OC3CCOCC3)[s]c(-c3ncc[o]3)c1C)=O)C2=O)=O Chemical compound CC(C)(C)OC(C(C)(C)N(C(c1c(N2CC(c3ccccc3OC)OC3CCOCC3)[s]c(-c3ncc[o]3)c1C)=O)C2=O)=O NFBQJHOKTSYEDJ-UHFFFAOYSA-N 0.000 description 1
- OFQVBQWUJXQONZ-ZFOQBMKHSA-N CCC(N(C)/C=C\O)N(C[C@@H](c1ccccc1OC)OC1CCOCC1)C(N(C(C)(C)C(NOCC)=O)C(CC)=O)=O Chemical compound CCC(N(C)/C=C\O)N(C[C@@H](c1ccccc1OC)OC1CCOCC1)C(N(C(C)(C)C(NOCC)=O)C(CC)=O)=O OFQVBQWUJXQONZ-ZFOQBMKHSA-N 0.000 description 1
- HEJXIWXNLPVQQL-UHFFFAOYSA-N CCONC(C(C)(C)N(C(c1c(N2CC(c3ccccc3OC)OC3CCOCC3)[s]c(-c3ncc[o]3)c1C)=O)C2=O)=O Chemical compound CCONC(C(C)(C)N(C(c1c(N2CC(c3ccccc3OC)OC3CCOCC3)[s]c(-c3ncc[o]3)c1C)=O)C2=O)=O HEJXIWXNLPVQQL-UHFFFAOYSA-N 0.000 description 1
- DBNLRXIWDMHQDJ-AWEZNQCLSA-N COc1ccccc1[C@H](CO)OC1CCOCC1 Chemical compound COc1ccccc1[C@H](CO)OC1CCOCC1 DBNLRXIWDMHQDJ-AWEZNQCLSA-N 0.000 description 1
- LMYJGUNNJIDROI-UHFFFAOYSA-N OC1CCOCC1 Chemical compound OC1CCOCC1 LMYJGUNNJIDROI-UHFFFAOYSA-N 0.000 description 1
Definitions
- R a is selected from a hydrogen atom or an alkyl group
- R 4 and R 5 are each independently selected from a hydrogen atom, an alkyl group, -OR 11 , -SR 11 , -NR 9 R 10 , -C(O)NR 9 R 10 , -C(O)R 11 , -OC (O) R 11 , -S(O) n NR 9 R 10 , -C(O)OR 11 or -NR 9 C(O)R 10 ;
- R 6 is selected from the group consisting of halogen, cycloalkyl, heterocyclic, aryl, heteroaryl, -NR 9 R 10 , -C(O)NR 9 R 10 , -C(O)R 11 , -OC(O) R 11 , -S(O) n NR 9 R 10 , -C(O)OR 11 or -NR 9 C(O)R 10 , preferably a heteroaryl group;
- R 1 and R 6 together with the atom to which they are attached form a 3 to 8 membered saturated or partially unsaturated cycloalkyl group, or form a hetero atom having one or more selected from N, O, S(O) n .
- cycloalkyl group, heterocyclic group, aryl group or heteroaryl group is optionally further subjected to one or A plurality selected from the group consisting of hydroxyl, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, -NR 9 R 10 , -C(O)NR 9 R 10, -C (O) R 11 , -OC (O) R 11, -S (O) n NR 9 R 10, -C (O) oR 11 or -NR 9 C (O) R 10 substituents Replace
- n 0, 1, or 2.
- the invention also provides the use of a compound of formula (I) or a pharmaceutical composition thereof for the manufacture of a medicament for the treatment or prevention of a disease or condition associated with ACC, wherein the disease or condition is preferably a metabolic disease, a cancer, a fungus a parasitic or bacterial infection; wherein the metabolic disease is preferably hepatic steatosis, nonalcoholic fatty liver, obesity, dyslipidemia, hyperlipidemia, type II diabetes or metabolic syndrome, wherein the obesity is preferred Is Prader-Willi syndrome, Bardet-Biedl syndrome or Cohen syndrome or MOMO syndrome, wherein the cancer is preferably liver Cell carcinoma, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, head and neck cancer, melanoma, ovarian cancer or cervical cancer, more preferably hepatocellular carcinoma and non-small cell lung cancer.
- the disease or condition is preferably a metabolic disease, a cancer, a fungus a parasitic or bacterial infection
- Examples of monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatriene
- the alkenyl group, the cyclooctyl group and the like are preferably a cyclopropyl group or a cyclohexenyl group.
- the spirocycloalkyl group is classified into a monospiro, a spiro- or a spirocycloalkyl group, preferably a mono- and bi-spirocycloalkyl group, preferably 4 yuan/5 yuan, 4, depending on the number of common spiro atoms between the rings. Yuan / 6 yuan, 5 yuan / 5 yuan or 5 yuan / 6 yuan.
- the heterocyclyl ring may be fused to an aryl, heteroaryl or cycloalkyl ring wherein the ring to which the parent structure is attached is a heterocyclic group.
- the heterocyclic group may be optionally substituted or unsubstituted.
- Heteroaryl means an aromatic 5 to 6 membered monocyclic or 9 to 10 membered bicyclic ring which may contain from 1 to 4 atoms selected from nitrogen, oxygen and/or sulfur.
- heteroaryl include, but are not limited to, furyl, pyridyl, 2-oxo-1,2-dihydropyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, thienyl, isoxazolyl , oxazolyl, oxadiazolyl, imidazolyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl, benzo Dioxolyl, benzimidazolyl, fluorenyl, isodecyl, 1,3-dioxo-isoindenyl, quinolyl, ox
- Amino means -NH 2 .
Abstract
Font l'objet de la présente invention des dérivés d'un hétéroaryle et d'une pyrimidinone de formule I, leur procédé de préparation et leur application thérapeutique, particulièrement leur application comme inhibiteurs de l'acétyl coenzyme A carboxylase (ACCase), la définition de chaque substituant de formule I étant semblable à celle contenue dans la description.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201880018956.0A CN110431143B (zh) | 2017-03-24 | 2018-03-23 | 杂芳基并嘧啶酮类衍生物及其制备方法和用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710182530.6 | 2017-03-24 | ||
CN201710182530 | 2017-03-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018171698A1 true WO2018171698A1 (fr) | 2018-09-27 |
Family
ID=63584121
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2018/080117 WO2018171698A1 (fr) | 2017-03-24 | 2018-03-23 | Dérivés d'un hétéroaryle et d'une pyrimidinone, leur procédé de préparation et leur application |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN110431143B (fr) |
WO (1) | WO2018171698A1 (fr) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10759812B2 (en) | 2017-01-22 | 2020-09-01 | Sunshine Lake Pharma Co., Ltd. | Thienopyrimidine derivative and use thereof in medicine |
WO2021000242A1 (fr) * | 2019-07-02 | 2021-01-07 | 广东东阳光药业有限公司 | Dérivés de thiénopyrimidine ayant des configurations stéréo et leur utilisation en médecine |
CN112739705A (zh) * | 2018-11-20 | 2021-04-30 | 中国医药研究开发中心有限公司 | 螺环类化合物及其医药用途 |
WO2022138812A1 (fr) | 2020-12-24 | 2022-06-30 | モジュラス株式会社 | Composé de tétrahydrothiénopyridinesulfonamide |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013071169A1 (fr) * | 2011-11-11 | 2013-05-16 | Nimbus Apollo, Inc. | Inhibiteurs de l'acc et utilisations associées |
WO2014182943A1 (fr) * | 2013-05-10 | 2014-11-13 | Nimbus Apollo, Inc. | Inhibiteurs de l'acc et utilisations associées |
WO2014182950A1 (fr) * | 2013-05-10 | 2014-11-13 | Nimbus Apollo, Inc. | Inhibiteurs de l'acc et utilisations associées |
WO2014182945A1 (fr) * | 2013-05-10 | 2014-11-13 | Nimbus Apollo, Inc. | Inhibiteurs de l'acc et leurs utilisations |
WO2017091617A1 (fr) * | 2015-11-25 | 2017-06-01 | Gilead Apollo, Llc | Inhibiteurs d'acc à base de triazole et utilisations associées |
WO2017091600A1 (fr) * | 2015-11-25 | 2017-06-01 | Gilead Apollo, Llc | Inhibiteurs de l'acc à base de pyrazole et utilisations associées |
WO2017091602A1 (fr) * | 2015-11-25 | 2017-06-01 | Gilead Apollo, Llc | Inhibiteurs de l'acc à base d'esters et utilisations associées |
-
2018
- 2018-03-23 WO PCT/CN2018/080117 patent/WO2018171698A1/fr active Application Filing
- 2018-03-23 CN CN201880018956.0A patent/CN110431143B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013071169A1 (fr) * | 2011-11-11 | 2013-05-16 | Nimbus Apollo, Inc. | Inhibiteurs de l'acc et utilisations associées |
WO2014182943A1 (fr) * | 2013-05-10 | 2014-11-13 | Nimbus Apollo, Inc. | Inhibiteurs de l'acc et utilisations associées |
WO2014182950A1 (fr) * | 2013-05-10 | 2014-11-13 | Nimbus Apollo, Inc. | Inhibiteurs de l'acc et utilisations associées |
WO2014182945A1 (fr) * | 2013-05-10 | 2014-11-13 | Nimbus Apollo, Inc. | Inhibiteurs de l'acc et leurs utilisations |
WO2017091617A1 (fr) * | 2015-11-25 | 2017-06-01 | Gilead Apollo, Llc | Inhibiteurs d'acc à base de triazole et utilisations associées |
WO2017091600A1 (fr) * | 2015-11-25 | 2017-06-01 | Gilead Apollo, Llc | Inhibiteurs de l'acc à base de pyrazole et utilisations associées |
WO2017091602A1 (fr) * | 2015-11-25 | 2017-06-01 | Gilead Apollo, Llc | Inhibiteurs de l'acc à base d'esters et utilisations associées |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10759812B2 (en) | 2017-01-22 | 2020-09-01 | Sunshine Lake Pharma Co., Ltd. | Thienopyrimidine derivative and use thereof in medicine |
CN112739705A (zh) * | 2018-11-20 | 2021-04-30 | 中国医药研究开发中心有限公司 | 螺环类化合物及其医药用途 |
CN112739705B (zh) * | 2018-11-20 | 2022-08-16 | 中国医药研究开发中心有限公司 | 螺环类化合物及其医药用途 |
WO2021000242A1 (fr) * | 2019-07-02 | 2021-01-07 | 广东东阳光药业有限公司 | Dérivés de thiénopyrimidine ayant des configurations stéréo et leur utilisation en médecine |
JP7374233B2 (ja) | 2019-07-02 | 2023-11-06 | ▲広▼▲東▼▲東▼▲陽▼光▲薬▼▲業▼有限公司 | 立体配置を有するチエノピリミジン誘導体及び薬物におけるその応用 |
WO2022138812A1 (fr) | 2020-12-24 | 2022-06-30 | モジュラス株式会社 | Composé de tétrahydrothiénopyridinesulfonamide |
Also Published As
Publication number | Publication date |
---|---|
CN110431143B (zh) | 2022-08-12 |
CN110431143A (zh) | 2019-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3184521B1 (fr) | Composés indazole utilisés comme inhibiteurs de la fgfr kinase, préparation et utilisation associées | |
WO2018171698A1 (fr) | Dérivés d'un hétéroaryle et d'une pyrimidinone, leur procédé de préparation et leur application | |
CN110709402B (zh) | 杂芳基并嘧啶酮类衍生物、其制备方法及其在医药上用途 | |
JP6035423B2 (ja) | 新規な縮合ピリミジン化合物又はその塩 | |
JP5501355B2 (ja) | 置換アルキルピリミジン−4−オン誘導体 | |
CA2894642A1 (fr) | Derives pyrimidone et leur utilisation dans le traitement, l'amelioration ou la prevention d'une maladie virale | |
CA2965981A1 (fr) | Chromanes substitues et methode d'utilisation | |
JP5943053B2 (ja) | フェノキシメチル複素環化合物 | |
EP2651899A2 (fr) | Composés hétérocycliques azotés substitués 6,6-fusionnés et leurs utilisations | |
WO2017076355A1 (fr) | Dérivé pyrimidine et son utilisation | |
TW201518278A (zh) | 吡啶酮類衍生物、其製備方法及其在醫藥上的應用 | |
US11535593B2 (en) | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | |
WO2022206723A1 (fr) | Dérivé hétérocyclique, son procédé de préparation et son utilisation en médecine | |
JPWO2004043936A1 (ja) | Plk阻害剤 | |
US9187459B2 (en) | Quinazoline-7-ether compounds and methods of use | |
WO2019085894A1 (fr) | Composé cyclique fusionné contenant de l'azote, son procédé de préparation et son utilisation | |
WO2017143874A1 (fr) | Composé chimique d'oxadiazole substitué et composition contenant ledit composé chimique, et utilisation associée | |
US11142531B2 (en) | Cyano substituted heteroarylpyrimidinone derivative, preparation method and use thereof | |
JP6847851B2 (ja) | Nmda受容体のモジュレーターとしてのピリドピリミジノン及びその使用 | |
EP1634883B1 (fr) | Derives phenyl-5,7-dialalkyl-3,7-dihydropyrrol[2,3-d] pyrimidine-4-one substitues en position 2, leur preparation et leur utilisation en pharmacie | |
CA3152508A1 (fr) | Composes de pyrrolopyrimidine inhibiteurs de perk | |
CN103664734A (zh) | 杂环羟肟酸类化合物及其药用组合物和应用 | |
TW202024020A (zh) | 治療神經退化性疾病之方法 | |
US20210284658A1 (en) | Novel thiazole derivatives and pharmaceutically acceptable salts thereof | |
CN115557949A (zh) | 四环类衍生物、其制备方法及其在医药上的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18770499 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18770499 Country of ref document: EP Kind code of ref document: A1 |